TERT and neoplasm: This includes consideration of molecular/genetic prognosticators, such as genome-wide methylation patterns (33, 34), TERT promoter mutations (35), and additional tumor molecular data given our findings, future investigations into unique genetic/molecular, clinical, and pathologic predictors of early and later recurrences are warranted as well, given the potential impact on therapeutic decision making by physicians.